Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.38 |
| ▸ | FER | P16591 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.34 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CDC25B | P30305 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209266 | 0.73 | TGM2 (0.36) | MAOBKDM4E | |
| SCHEMBL207191 | 0.73 | CES1 (0.44) | LTKCDK8ACVR1LRRK2DYRK1B | |
| SCHEMBL207213 | 0.73 | CMA1 (0.40) | LRRK2KMT2AMEN1CES1 | |
| SCHEMBL211048 | 0.73 | TGM2 (0.44) | LRRK2GSK3BKMT2AMEN1CES1 | |
| SCHEMBL208827 | 0.73 | PARP1 (0.38) | LRRK2KMT2AMEN1KDM4E | |
| SCHEMBL19678 | 0.69 | — | — | |
| SCHEMBL21311994 | 0.67 | LRRK2 (0.58) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL1551702 | 0.67 | MAOA (0.41) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL68595 | 0.67 | CA12 (0.45) | MAOAMAOBPDGFRAFERLTK | |
| SCHEMBL61310 | 0.67 | CA12 (0.50) | MAOAMAOBGSK3BKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239857-A1 | TRIAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-24 | — | — | US | claimed |
| US-7576135-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-08-18 | — | — | US | claimed |
| EP-1864982-A1 | TRIAMINE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-12-12 | — | — | EP | claimed |
| US-20070129371-A1 | Novel ethylenediamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-06-07 | — | — | US | claimed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | claimed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | claimed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | claimed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | claimed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | claimed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | claimed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | claimed |
| EP-4362917-A2 | AEROSOL COMPOSITION FOR PULMONARY DELIVERY OF FLAGELLIN | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023275292-A2 | AEROSOL COMPOSITION FOR PULMONARY DELIVERY OF FLAGELLIN | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-01-05 | — | — | WO | disclosed |
| US-10736937-B2 | Methods and pharmaceutical compositions for the treatment of bacterial superinfections post-influenza | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2020-08-11 | — | — | US | disclosed |
| EP-3236988-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BACTERIAL SUPERINFECTIONS POST-INFLUENZA | INST NAT SANTE RECH MED (FR) | 2020-06-24 | — | — | EP | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
| US-4616014-A | HYPOTENSIVE AGENTS, ANTICOAGULANTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-10-07 | — | — | US | disclosed |
| EP-0077983-A1 | Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129371-A1 | Novel ethylenediamine derivatives | C1R, C9, C1S | MAOA 2820/4885MAOB 1441/4885PDGFRA 2189/4885 |
| US-20090239857-A1 | TRIAMINE DERIVATIVE | F2, F12, F3 | MAOA 65/4885MAOB 208/4885PDGFRA 60/4885 |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | MAOA 2552/4885MAOB 2043/4885PDGFRA 2476/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | MAOA 3264/4885MAOB 2147/4885PDGFRA 3407/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | MAOA 3264/4885MAOB 2147/4885PDGFRA 3407/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | MAOA 3264/4885MAOB 2147/4885PDGFRA 3407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.